May 7
ENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer
Read moreBrandon BioCatalyst is the largest life science investment fund in Australia and New Zealand. We are a unique collaboration between CSL, major Australian superannuation funds, the Australian and New Zealand governments, Australian state governments and more than 50 leading medical research institutes and research hospitals.
Learn more about who we areA clinical stage company developing treatment for hot flashes in cancer survivors undergoing endocrine therapy
View ProjectDeveloping disease-modifying mitochondrial therapeutics for neurodegenerative disorders
View ProjectDeveloping the next generation of CAR-T cell therapies to treat solid cancers
View ProjectCombining non-opioid analgesics and biopolymers to deliver weeks of localised pain management
View ProjectUnlocking the potential of N-myristoyltransferase (NMT) to develop precision medicines for a range of diseases including cancer and viral infections
View ProjectGlyscend is developing novel non-absorbable polymers that are orally-delivered for the treatment of Type 2 Diabetes.
View ProjectHudson Institute of Medical Research is a leading Australian medical research institute recognised internationally for discovery science and translational research into reproductive health and pregnancy, infant and child health, inflammation and cancer.
ViewThe Heart Research Institute (HRI) is an internationally recognised research institute that performs cutting-edge cardiovascular research. The main focus of this research is to gain an understanding of the development and progression of atherosclerosis, the dominant cause of cardiovascular disease.
ViewThe MRCF collaboration is innovation in action: We provide a path for taking medical science from conception into the real world.
Our Venture capital model is unique. We don’t simply provide investment, we create businesses, run companies and everything necessary to ensure our investments succeed.
Learn moreENA Respiratory Appoints International Pharma Experts as Strategic Advisors to Support Development of INNA-051 Antiviral Host Defence Enhancer
Read moreThrough a different lens: How Kath Giles and OncoRes Are Reinventing Breast Cancer Surgery
Read moreENA Respiratory: The Difference Between Chance and Discovery? Knowing What to Do Next.
Read moreMeet Proxima Bio: Australia’s next-generation biotech startup aiming to clean up cancer-causing proteins.
Read more